Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for preparing (R)-3,5-bis(trifluoromethyl)phenethyl alcohol in ionic liquid-containing cosolvent medium

A technology of trifluoromethyl phenethyl alcohol and ionic liquid, which is applied in the field of biological reduction to prepare -3,5-bis-trifluoromethyl phenethyl alcohol, can solve problems such as low yield, reduce inhibition effect and increase substrate concentration , the effect of improving the reaction efficiency

Active Publication Date: 2014-12-17
南陵县建设投资有限责任公司
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The method is carried out in an aqueous phase system, and only at a lower substrate concentration (50mM), the yield can reach more than 90%. When the substrate concentration is greater than 200mM, due to the substrate 3,5-bistrifluoroform The mass transfer problem caused by the low solubility of phenylacetophenone in the aqueous phase, and the potential toxicity of the substrate to cells limit the further increase of the substrate concentration of the reaction, resulting in low yield

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing (R)-3,5-bis(trifluoromethyl)phenethyl alcohol in ionic liquid-containing cosolvent medium
  • Method for preparing (R)-3,5-bis(trifluoromethyl)phenethyl alcohol in ionic liquid-containing cosolvent medium
  • Method for preparing (R)-3,5-bis(trifluoromethyl)phenethyl alcohol in ionic liquid-containing cosolvent medium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1: Construction of Leifsonia xyli (Leifsonia xyli) HS0904 short-chain dehydrogenase mutant

[0032] Using the plasmid pET28a(+) containing short-chain dehydrogenase derived from Leifsonia xyli HS0904 as a template, the mutant LXCAR was obtained by error-prone PCR and site-directed mutagenesis. The C at position 461 in the nucleotide sequence is mutated to A, and the G at position 462 is mutated to T; the serine at position 154 in the corresponding amino acid sequence is mutated to tyrosine (the nucleotide sequence is shown in SEQ ID NO.3, encoding The amino acid sequence of the protein is shown in SEQ ID NO.4). The obtained short-chain dehydrogenase mutant gene was ligated with the expression plasmid pET28a(+) and then transformed into Escherichia coli BL21(DE3), thereby constructing the short-chain dehydrogenase mutant containing Leifsonia xyli HS0904 Recombinant Escherichia coli BL21(DE3) / pET28a(+)-LXCAR with body gene.

Embodiment 2

[0033] Embodiment 2: the preparation method of wet thalline used in the embodiment of the present invention

[0034] The recombinant Escherichia coli BL21(DE3) / pET28a(+)-LXCAR obtained from the construction was inoculated in LB liquid medium containing 50 μg / mL kanamycin, cultured with shaking at 37°C and 200 rpm for 12 hours, and then injected with 1% volume concentration of The inoculum was inoculated into fresh LB liquid medium containing 50 μg / mL kanamycin, and cultured at 37°C and 200 rpm to the cell concentration OD 600 After the temperature is about 0.6 to 0.9, add isopropyl-B-D-thiogalactopyranoside (IPTG) at a final concentration of 0.1 mmol / L to the culture medium, and place it at 30°C and 200 rpm for 10 hours to induce culture. After the cultivation, centrifuge at 4°C and 10,000 rpm for 10 minutes to collect the cells, wash the cells with physiological saline twice, and collect the wet cells, which are wet cells of recombinant Escherichia coli.

Embodiment 3

[0036] Respectively, the recombinant engineering bacteria (before mutation) containing the short-chain dehydrogenase gene derived from Leifsonia xyli (Leifsonia xyli) HS0904 and the mutant gene containing the short-chain dehydrogenase derived from Leifsonia xyli (Leifsonia xyli) HS0904 Recombinant engineered bacteria (after mutation) are used as biocatalysts to prepare (R)-3,5-bistrifluoromethylphenethyl alcohol ((R) by catalytic asymmetric reduction of 3,5-bistrifluoromethylacetophenone (BTAP) )-BTPE) performance comparison.

[0037] The method is as follows (the total volume of the reaction system is 5 mL): in a 50 mL Erlenmeyer flask, add 20 g / L (wet weight) of recombinant E. coli wet thallus, 3.92 mL of phosphate buffer (200 mM, pH7.2), 20% (v / v ) of isopropanol and 200 mM of the substrate (BTAP). React at 30° C. and 200 rpm for 4 hours. After the reaction, the reaction solution was extracted with an equal volume of ethyl acetate, and the ethyl acetate phase was used for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for preparing (R)-3,5-bis(trifluoromethyl)phenethyl alcohol in an ionic liquid-containing cosolvent system. The method is characterized in that an ionic liquid is added to a reaction system during asymmetric reduction of 3,5-bis(trifluoromethyl)acetophenone by use of genetically engineered recombinant bacteria; the permeability of the cytomembrane is improved and a substrate is solubilized so that the solubility of the substrate can be effectively improved and the inhibition effect of the substrate and the product on the reaction can be reduced; as a result, the substrate concentration and the reaction efficiency of the reaction are improved; the substrate concentration of the reaction is increased to 1200mM from 50mM; besides, when the substrate concentration is 1200mM, the yield is increased to 93.8% from 70.4% of water phase reduction; the yield is increased by 33.2%; the ee value is greater than 99%.

Description

(1) Technical field [0001] The present invention relates to a genetically engineered bacterium and its application, in particular to a recombinant Escherichia coli engineered bacterium and its bioreduction preparation of (R)-3,5-bistrifluoromethylphenylethanol in an ionic liquid co-solvent system method. (2) Background technology [0002] In 2003, the US FDA approved the first neurokinin-1 (NK-1) receptor blocker drug, namely Aprepitant (trade name: ). The drug achieves the antiemetic effect by binding to NK-1 receptors to block the action of substance P, and is widely used in the treatment of side effects of malignant vomiting in cancer patients during chemotherapy. In 2008, another antiemetic drug, Fosaprepitant (trade name: ), the drug is the prodrug of aprepitant, which can be rapidly converted into aprepitant in the body to exert an antiemetic effect. (R)-3,5-Bistrifluoromethylphenethyl alcohol is a key chiral module for the synthesis of chemotherapeutic antiemeti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12R1/19C12P7/22
Inventor 王普王能强黄金李军
Owner 南陵县建设投资有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com